Introduction
Administration of intrapartum magnesium sulfate is recommended for fetal neuroprotection in women presenting with imminent preterm birth at <32 weeks' gestation. 1 This practice is supported by meta-analyses that showed administration of intrapartum magnesium sulfate was associated with a reduced risk of cerebral palsy (CP) in preterm infants. 2e4 However, previous clinical trials did not include or analyze the outcomes of pregnancies with fetal growth restriction. 5e9 It is unclear whether administration of magnesium sulfate to pregnancies with fetal growth restriction can reverse the consequences of adverse brain growth associated with fetal growth restriction as some of the processes for neuronal injury may have been established already in such fetuses. 10e12 Moreover, borderline high ionized magnesium levels in cord blood were observed in growth-restricted fetuses when compared to healthy term newborns, though neither group was exposed to intrapartum magnesium sulfate. 13 Thus, intrapartum magnesium sulfate could lead to levels of magnesium that are neurotoxic in growth-restricted fetuses. To our knowledge, there are no published studies evaluating the safety and long-term effects of intrapartum magnesium sulfate in growth-restricted fetuses. 12 Thus, our objective was to compare the neonatal and neurodevelopmental outcomes of growthrestricted fetuses born <29 weeks' gestation who received intrapartum magnesium sulfate for neuroprotection with those who did not receive magnesium sulfate.
Materials and Methods

Design and participants
We conducted a retrospective cohort study using data collected for the Canadian Neonatal Network (CNN) and the Canadian Neonatal Follow-up Network (CNFUN) as part of our wider initiative, the Canadian Preterm Birth Network. 14 Growth-restricted infants of <29 weeks' gestation born from Jan. 1, 2010, through Sept. 30, 2011 , who were admitted to one of the tertiary neonatal intensive care units (NICUs) participating in the CNN and were assessed in neurodevelopmental follow-up clinics at 18e36 months' corrected age were included. We have included only infants <29 weeks' gestation as these infants are at very high risk of neurodevelopmental impairment (NDI) so we have targeted to have standardized follow-up of such infants in a national cohort in Canada. 15 and neonatal 16 growth standards, respectively. We assumed that actual birthweight was the same as estimated fetal weight because when magnesium sulfate is administered the maternal care provider is only aware of the estimated fetal weight. We also analyzed data using neonatal classification of small for gestational age as this included the correct birthweight information. Infants were subdivided into 2 groups: infants exposed to intrapartum magnesium sulfate and infants not exposed to intrapartum magnesium sulfate. Infants with major congenital or chromosomal anomalies, planned palliative care prior to birth, or missing data were excluded. Mount Sinai Hospital's Research Ethics Board and the steering committees of CNN and CNFUN approved data collection and analyses.
Outcomes
The primary outcome was composite of death or significant NDI (sNDI) defined as any of the CP with Gross Motor Function Classification System (GMFCS) 17 score III; or Bayley Scales of  Infant and Toddler Development-third  edition (BSID-III) 18 motor, language, cognitive, or general adaptive composite scores of <70; or severe developmental delay that precluded the use of BSID-III for assessment at 18e36 months' corrected age. Secondary outcomes were death or any NDI defined as any of the CP with GMFCS score I or any BSID-III component score of <85 in any domain. 19 Sensory impairments were unlikely affected by magnesium sulfate; thus, vision and hearing impairments were not included in the definition of NDI. Target neurodevelopmental assessment age was 18e21 months' corrected age. A few difficult-to-track participants were seen >21 months; median assessment age was 18 months' corrected age. Common neonatal morbidities defined below were also compared.
Data collection
Patient data were collected by the CNN and CNFUN across all centers using standard manuals of operations and definitions. 20, 21 The CNN database was shown to have high consistency and reliability. 22 Eligible infants were identified within the CNN database and linked to the CNFUN database using a unique identifier. The CNN covered 28 NICUs and CNFUN all 26 follow-up clinics during the study period encompassing w90% of eligible infants born during the study period in Canada.
Variables obtained from the CNN database were: (1) growth restriction, defined as both estimated and actual weight <10th percentile for gestational age and sex according to fetal and neonatal growth standards as described above; (2) exposure of intrapartum magnesium sulfate; (3) maternal and neonatal characteristics; (4) common neonatal morbidities; and (5) At 18e36 months' corrected age, children were assessed at affiliated CNFUN sites by specialized clinicians whenever possible, and 6% of assessments were by community health care professionals. The assessment included a standardized history, physical and neurological examinations, and administration of the BSID-III test to obtain cognitive, language, and motor scores. In cases where the child could not be tested, the BSID-III Adaptive Behavior questionnaires were administered. A diagnosis of CP was made using standard definitions 27 and if CP was present, the degree of functional impairment was classified using the GMFCS.
Statistical analysis
Maternal and infant characteristics, as well as the primary and secondary outcomes, were compared among infants exposed and unexposed to intrapartum magnesium sulfate. Frequency (percentage), mean (SD), or median (interquartile range) were reported.
Differences were assessed by Pearson c 2 for categorical variables, and Student t test or Wilcoxon rank test for continuous variables. Multivariable logistic analyses were applied for primary and secondary outcomes. Adjusted odds ratios (aORs) and 95% confidence intervals were estimated. Confounding factors included the following: maternal hypertension,
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ajog.org OBSTETRICS Original Research cesarean delivery, multiple gestations, gestational age, male sex, and Score for Neonatal Acute Physiology-II score >20. All analyses were conducted using software (SAS 9.3; SAS Institute Inc, Cary, NC) with 2-sided significance level .05.
Results
Of the 2777 infants admitted to one of the participating CNN NICUs from January 1, 2010, through September 30, 2011, 447 infants were growth-restricted fetuses according to fetal growth standards and 227 infants were growth restricted according to neonatal growth standards. After applying exclusion criteria, 336 suspected growth-restricted fetuses remained, of which 112 (33%) were exposed to magnesium sulfate and 177 infants were growth restricted by birthweight standards, of whom 61 (34%) were exposed to magnesium sulfate ( Figure) . All infants identified as growth restricted by birthweight were classified as growth-restricted fetuses using fetal growth standards.
The maternal and neonatal characteristics varied between growthrestricted infants exposed and not exposed to intrapartum magnesium sulfate (Table 1) . Significantly more growth-restricted infants exposed to magnesium sulfate had mothers with hypertension, as well as fewer multiple gestations in exposed infants, in both growth restriction categories. Gestational age, prolonged rupture of membrane, and cesarean deliveries were also variable in growth-restricted fetuses as defined by the fetal growth standard. Table 2 shows aORs of common neonatal morbidities. Intrapartum magnesium sulfate was associated with reduced odds of mortality, both in the NICU and postdischarge. However, the odds of intraventricular hemorrhage, late-onset sepsis, bronchopulmonary dysplasia, necrotizing enterocolitis, and severe ROP were not statistically significantly different between the infants exposed and unexposed to magnesium sulfate. Table 3 presents aORs for the primary and secondary outcomes. Intrapartum magnesium sulfate was associated with significantly reduced odds of death or sNDI in growth-restricted infants. Odds of death or any NDI were not different between groups. Rates of CP were lower in growth-restricted fetuses exposed to intrapartum magnesium sulfate; however, the adjusted odds were not different between groups. BSID-III composite motor scores were significantly higher in magnesium sulfateeexposed group than the unexposed group in both growth restriction categories. No significant differences were seen in the adjusted difference in mean of BSID-III composite scores in cognitive and language skills between those exposed and unexposed to intrapartum magnesium sulfate.
Comment
Principal findings
In this population-based cohort study, we identified that death or sNDI at 18e36 months' corrected age was significantly lower in growth-restricted fetuses exposed to intrapartum magnesium sulfate. The results were similar whether we used fetal growth standards or neonatal birthweight standards to classify growth restriction. Correspondingly, we identified higher composite motor scores among magnesium sulfateeexposed infants than unexposed infants. Mortality during NICU admission and postdischarge was also significantly lower in magnesiumexposed infants than unexposed infants. Finally, the majority of outcome rates were lower in magnesium sulfateeexposed growth-restricted fetuses than unexposed; however, in adjusted analyses there were no differences between the groups.
Results in context
Our study is the first to specifically evaluate the effects of intrapartum magnesium sulfate in growth-restricted fetuses. There have been 5 randomized controlled trials evaluating the use of intrapartum magnesium sulfate for antenatal neuroprotection, but none of them have specifically examined a subgroup of growth-restricted fetuses. Crowther et al 5 evaluated the use of intrapartum magnesium sulfate when delivery was imminent in infants born at <30 weeks' gestation. They found a statistically significant reduction in substantial gross motor dysfunction and death or substantial gross motor dysfunction but not in mortality, CP, and combined death or CP at 24 months' corrected age in infants exposed to magnesium sulfate. The PREMAG trial 7 assessed the effectiveness of intrapartum magnesium sulfate in preventing mortality, white-matter injury, or both ajog.org
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in infants born <33 weeks' gestation. They also reported a nonstatistically significant reduction in neonatal mortality, severe white-matter injury, and combined outcome of severe whitematter injury and/or mortality at discharge in infants who received magnesium sulfate. Rouse et al 9 investigated the effects of intrapartum magnesium sulfate by rates of death at 12 months' corrected age or moderate-severe CP at 24 months' corrected age in infants born between 24e31 weeks' gestation. They found that moderate or severe CP occurred less frequently in infants exposed to magnesium sulfate, but unlike our study, the risk of death was similar in infants exposed or unexposed to magnesium sulfate. The Magpie trial 6 was primarily designed to determine the maternal effects of magnesium sulfate, but also reported on neonatal outcomes. They noted a lower risk of death or CP at 24 months' corrected age in infants exposed to magnesium sulfate, but again the difference did not reach statistical significance. Last, the findings of Mittendorf et al 8, 28 are in contrast to both our study and others. They reported significantly higher pediatric mortality rates, as well as adverse outcomes (a composite of neonatal intraventricular hemorrhage, periventricular leukomalacia, CP, or death) in infants exposed than unexposed to intrapartum magnesium sulfate at 18 months' corrected age. In 2009, 3 meta-analyses 2e4 concluded that magnesium sulfate given for fetal neuroprotection reduced the risk of CP. Our data add to the evidence showing that intrapartum magnesium sulfate could be safe and beneficial, even in growth-restricted fetuses.
Our choice to use both fetal and neonatal standards for growth restriction highlights the difference in cut-offs used by obstetricians and neonatologists. This has been investigated previously in detail with incidence of growth restriction diagnosis approximately 20e25% by fetal standards and 10% by neonatal standards. 29 Results from both cut-offs in our study pointed to similar results in outcomes; however, it adds to ongoing debate regarding the use of numerical cut-off, outcome-based cut-off, local population-based cut-off, universal cutoff, or combined criteria 30e33 for diagnosis of fetal/neonatal growth restriction.
Potential mechanism of action
The association of magnesium sulfate with reduced sNDI fits with magnesium sulfate's role as a key mediator in molecular pathways that regulate apoptosis secondary to inflammation and hypoxic-ischemic injury. 34 Although the exact mechanism of magnesium sulfate has yet to be elucidated, hypotheses include blocking the Nmethyl-D-aspartate receptor, competitively reducing entry of intracellular calcium, modulating the actions of proinflammatory cytokines and oxygenfree radicals, and reducing vascular instability thereby stabilizing blood pressure and cerebral arterial perfusion.
34e36 Our study evaluated intrapartum magnesium sulfate use given for any indication. Our cohort was born in 2010 and 2011 after the metaanalyses 2e4 were published, and during the period the Canadian guidelines 1 were published in 2011. Following professional guidelines, it is not uncommon for clinicians to administer the intervention to all comers rather than exclusively patients who were eligible in the original clinical trials. Thus, it is imperative to evaluate the impact of practices in vulnerable subgroups to ensure the practice does not lead to adverse consequences. However, De Silva et al 37 showed that overuse of magnesium sulfate for fetal neuroprotection to prevent CP was not a significant problem. 
Clinical implications
The fact that one third of our cohort received magnesium sulfate indicates that there was some awareness; however, there is a need for improved knowledge translation. From our previous reports we know that the rates of intrapartum magnesium sulfate administration have increased slowly from 40e65% over the last 6 years. 38 Our study supports the use of intrapartum magnesium sulfate for growth-restricted fetuses and suggests that intrapartum magnesium sulfate use can be reliably adopted for growth-restricted fetuses; however, our sample size is small and additional evaluation is required.
Research implications
Our results need to be confirmed in further studies as our numbers are relatively small. This is also evident from the results of many of the secondary outcomes, which indicate point estimate of odds ratio being <1 but confidence interval crossing 1. In addition, we also need to study longer term neurodevelopmental outcomes at school age to assess the safety of magnesium sulfate. The majority of trials have evaluated infants <32 weeks' gestation and it may be worthwhile to evaluate infants 29e32 weeks' gestation in future studies.
Strengths and limitations
The strengths of this study include the population-based cohort, robust data collection, and detailed analysis of the association of intrapartum magnesium sulfate on neonatal morbidities and neurodevelopment. We also analyzed data by both pragmatic fetal standards and stricter neonatal growth standards. However, we acknowledge that our study has several limitations. First, this was retrospective observational study with a relatively small sample size. However, looking at the challenges of such trials, we do not expect another large-scale trial focused only on growth-restricted fetuses. Second, we have w20% loss to follow-up in our cohort. In our previous reports we identified that those lost to follow-up were somewhat larger and more mature infants; however, it is possible that attrition could have impacted our results. However, there was no differential loss of follow-up in 2 groups. Third, our database only contains birthweight and does not collect data on estimated fetal weight. We used fetal growth standards and applied those values to actual birthweight assuming that if clinicians had estimated fetal weight data they will correspond with actual birthweight data. This assumption could be challenged; however, we believe that at population level our assumption will hold true on average. Forth, we do not have data on dose and duration of magnesium sulfate in our database and were therefore unable to quantify exposure amount and duration. Fifth, we did 
Conclusion
In conclusion, the administration of magnesium sulfate to women with growth-restricted fetuses immediately prior to preterm birth was associated with a reduced odds of death or sNDI at 18e36 months' corrected age for infants born at <29 weeks' gestation. n
